NCT04901325

Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Oregon Health and Science University · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum

Detailed description

This is a Phase II study that will be open label and include a total of 20 patients who will receive the investigational product. PG will be defined by the investigator and a second reviewer on the basis of results from clinical, histological and laboratory assessments. These patients will undergo 24 weeks of baricitinib dosed daily and stable dose of prednisone dosed daily with follow-up until week 36.

Conditions

• Pyoderma Gangrenosum
• Skin Diseases
• Wound Heal
• Pyoderma
• Skin Ulcer

Interventions

Type	Name	Description
DRUG	Baricitinib	Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.

Timeline

• Start date: 2023-10-03
• Primary completion: 2025-01-05
• Completion: 2025-05-07
• First posted: 2021-05-25
• Last updated: 2025-05-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study